Compare Morgan Stanley (MS) vs Summit Therapeutics Inc (SMMT) Price & Performance

Morgan Stanley (MS) trades at $187.41, down 1.21% on the day, with a bearish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing to $66.0 billion in 2025 and net income reaching $16.9 billion, alongside three consecutive quarterly EPS beats. Analysts maintain a bullish stance with a $229.25 consensus price target, citing growth in wealth management and AI financing.

The outlook is positive given earnings momentum and strategic growth areas, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to analyst targets if execution continues, though macroeconomic and capital markets volatility pose headwinds.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.